BCL2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A2780 ovarian adenocarcinoma line, designed to disrupt the BCL2 gene. This model provides a heterogeneous knockout background, avoiding clonal artifacts and preserving genetic diversity for functional studies of BCL2-dependent apoptosis. The polyclonal format supports applications requiring robust gene disruption without the limitations of single-cell clones.
The parental A2780 cell line was established from an untreated patient with endometrioid ovarian adenocarcinoma and is widely used as a cisplatin-sensitive epithelial ovarian cancer model. It retains tumorigenic properties and provides a relevant system for studying ovarian carcinoma signaling pathways that regulate cell survival and drug response. The epithelial origin and genetic background of A2780 make it especially suitable for investigating BCL2-mediated anti-apoptotic mechanisms in a solid tumor context.
BCL2 encodes an anti-apoptotic BCL-2 family protein that localizes to the mitochondrial outer membrane, where it binds and inhibits BAX and BAK, preventing mitochondrial outer membrane permeabilization and cytochrome c release. This blockade prevents apoptosome formation and activation of caspase-9 and executioner caspases-3/7. BCL2 expression is positively regulated by STAT3, NF-??B, AKT, IL-6, and estrogen receptor, and negatively by p53. BCL2 interacts with pro-apoptotic BH3-only proteins BIM, BID, PUMA, NOXA and anti-apoptotic BCL-xL and MCL-1. Loss of BCL2 removes an anti-apoptotic barrier, enabling cytochrome c release and caspase activation.
In the A2780 ovarian cancer context, BCL2 is frequently upregulated and linked to cisplatin resistance, making it a key determinant of chemosensitivity. Knockout of BCL2 in this polyclonal population is expected to enhance intrinsic apoptosis and may sensitize cells to DNA-damaging agents or targeted BCL2 inhibitors such as venetoclax. This model allows dissection of BCL2-dependent survival signaling and the interplay with other anti-apoptotic family members like MCL-1 and BCL-xL, revealing potential compensatory mechanisms and synthetic lethal interactions. By eliminating BCL2, researchers can investigate residual apoptotic blocks and identify strategies to overcome chemoresistance in ovarian cancer.
These BCL2 knockout cells are suitable for a variety of research applications, including apoptosis mechanism studies, chemoresistance profiling, BCL2 inhibitor screening, and drug synergy analysis. Typical assays include western blotting for BCL2, BAX, and cleaved caspases-3/9; cytochrome c release measurements; flow cytometry for apoptosis (Annexin V/PI); caspase activity assays; cell viability assessments (MTT/CellTiter-Glo); co-immunoprecipitation of BCL2 with pro-apoptotic partners; RNA-seq for transcriptomic analysis; and drug sensitivity testing with cisplatin or venetoclax. For further details or custom applications, please contact Ascent Research.
